Cantor Fitzgerald Predicts Atyr PHARMA FY2026 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Atyr PHARMA in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn ($0.78) per share for the year. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share.

Other equities analysts also recently issued reports about the stock. Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Leerink Partners started coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research report on Wednesday, June 4th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Stock Performance

Shares of Atyr PHARMA stock opened at $5.50 on Wednesday. The stock’s 50-day moving average is $3.60 and its 200-day moving average is $3.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA has a one year low of $1.42 and a one year high of $5.98. The firm has a market cap of $489.52 million, a price-to-earnings ratio of -5.85 and a beta of 0.88.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02.

Hedge Funds Weigh In On Atyr PHARMA

Several institutional investors and hedge funds have recently made changes to their positions in ATYR. D.A. Davidson & CO. bought a new stake in Atyr PHARMA in the fourth quarter valued at $141,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Atyr PHARMA during the fourth quarter valued at approximately $144,000. Victory Capital Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter worth $37,000. Raymond James Financial Inc. purchased a new position in shares of Atyr PHARMA during the fourth quarter valued at approximately $39,000. Finally, Farther Finance Advisors LLC bought a new position in shares of Atyr PHARMA during the 4th quarter valued at $88,000. Institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.